Cargando…
Open-label, multi-center, phase II study of adjuvant pemetrexed plus cisplatin for completely resected stage IB to IIIA adenocarcinoma of the lung: APICAL trial
BACKGROUND: We aimed to evaluate the efficacy of postoperative adjuvant pemetrexed plus cisplatin (Pem-Cis) in pathologic stage IB–IIIA lung adenocarcinoma (LUAD) patients. METHODS: A prospective, phase II study was performed in seven institutions in South Korea. Patients with completely resected st...
Autores principales: | Park, Cheol-Kyu, Oh, Hyung-Joo, Yoo, Seung Soo, Lee, Shin Yup, Lee, Sang Hoon, Kim, Eun Young, Lee, Sung Yong, Choi, Juwhan, Lee, Min Ki, Kim, Mi-Hyun, Jang, Tae Won, Chung, Chaeuk, Oh, In-Jae, Kim, Young-Chul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459613/ https://www.ncbi.nlm.nih.gov/pubmed/36090637 http://dx.doi.org/10.21037/tlcr-22-183 |
Ejemplares similares
-
Role of adjuvant treatment in stage IB non-small cell lung carcinoma
por: Park, Cheol-Kyu, et al.
Publicado: (2023) -
Adjuvant Treatment after Surgery in Stage IIIA Endometrial Adenocarcinoma
por: Yoon, Mee Sun, et al.
Publicado: (2016) -
Pharmacogenomic Assessment of Outcomes of Pemetrexed-Treated Patients with Adenocarcinoma of the Lung
por: Jung, Minkyu, et al.
Publicado: (2013) -
Predictive factors for long‐term responders of pemetrexed maintenance treatment in non‐small cell lung cancer
por: Yoon, Joon‐Young, et al.
Publicado: (2019) -
Clinical efficacy of adjuvant chemotherapy in stage IB (< 4 cm) non-small cell lung cancer patients with high-risk factors
por: Choi, Juwhan, et al.
Publicado: (2022)